IMRRT for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma

IMRRT 治疗局部复发性头颈鳞状细胞癌

• 批准号: 10926366
• 负责人: Vassiliki Saloura
• 金额: $ 1.4万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10926366
• 关键词: Apoptosis; BIRC2 gene; Biological Markers; Blood; Blood specimen; CASP3 gene; CD8-Positive T-Lymphocytes; Cell Death Induction; Collaborations; Drug Kinetics; Drug Targeting; Early Therapeutic-Clinical Trials Network; Genes; Goals; Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Immune; Maximum Tolerated Dose; Mutation; Ohio; Patients; Progression-Free Survivals; Qualifying; Radiation therapy; Radiation-Sensitizing Agents; Recurrence; Toxic effect; Tumor Tissue; United States National Institutes of Health; Universities; cIAP1 protein; cancer cell; cancer infiltrating T cells; exome sequencing; head and neck cancer patient; improved; irradiation; objective response rate; peptidomimetics; pharmacodynamic biomarker; phase I trial; programmed cell death ligand 1; response; safety assessment; transcriptome sequencing

Approximately 30% of head and neck cancer patients have a recurrent amplification in the FADD/BIRC2 (IAP1) genes. Inhibitor of apoptosis protein 1 is inhibited by SMAC. Birinapant is a peptidomimetic of SMAC, which inhibits IAP1 and has been shown to induce cell death in cancer cells with the specific amplification. In this phase I trial, patients with locoregionally recurrent head and neck cancer who have been previously treated with radiotherapy and qualify for re-irradiation, will receive birinapant in combination with re-irradiation. This trial opened in March 2019 at the NIH and in June 2019 in a collaborating ETCTN center (Ohio State University). We are expecting accrual of 1 patient per month.

在FADD/BIRC2（IAP1）基因中，大约30％的头颈癌患者复发了扩增。 SMAC抑制凋亡蛋白1的抑制剂。 Birinapant是SMAC的肽瘤，它抑制了IAP1，并已证明可以诱导具有特定扩增的癌细胞中的细胞死亡。在此I阶段试验中，先前接受过放疗并有资格重新辐照的局部复发性头颈癌的患者将获得Birinapant，并结合重新辐照。该试验于2019年3月在NIH开幕，并于2019年6月在俄亥俄州立大学的ETCTN中心合作。我们预计每月有1名患者。

项目成果

A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.

• DOI: 10.1002/hed.25910
• 发表时间: 2019-11
• 期刊: Head & neck
• 作者: Brisson RJ;Kochanny S;Arshad S;Dekker A;DeSouza JA;Saloura V;Vokes EE;Seiwert TY
• 通讯作者: Seiwert TY

Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma

• DOI: 10.1080/2162402x.2019.1568813
• 发表时间: 2019-01-01
• 期刊: ONCOIMMUNOLOGY
• 影响因子: 7.2
• 作者: Ren, Lili;Leisegang, Matthias;Nakamura, Yusuke
• 通讯作者: Nakamura, Yusuke